Versor Investments LP Takes Position in Kenvue Inc. (NYSE:KVUE)

Versor Investments LP acquired a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 15,600 shares of the company's stock, valued at approximately $333,000.

A number of other institutional investors also recently bought and sold shares of KVUE. Proficio Capital Partners LLC acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $1,643,000. Kovack Advisors Inc. acquired a new stake in Kenvue during the 4th quarter valued at $267,000. Lake Street Advisors Group LLC increased its position in Kenvue by 17.4% during the fourth quarter. Lake Street Advisors Group LLC now owns 15,919 shares of the company's stock worth $340,000 after buying an additional 2,361 shares in the last quarter. Longbow Finance SA raised its holdings in shares of Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after acquiring an additional 13,287 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Kenvue by 1,415.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 139,684 shares of the company's stock valued at $2,982,000 after acquiring an additional 130,467 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock traded down $0.11 during midday trading on Wednesday, hitting $23.31. The company had a trading volume of 8,335,108 shares, compared to its average volume of 14,445,545. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The business's 50 day simple moving average is $21.54 and its two-hundred day simple moving average is $22.30. The stock has a market cap of $44.55 billion, a PE ratio of 43.98, a P/E/G ratio of 2.62 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. Canaccord Genuity Group decreased their price objective on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $23.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.